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Case report Effective cardiac resynchronization therapy for an 
adolescent patient with dilated cardiomyopathy 
seven years after mitral valve replacement and 
septal anterior ventricular exclusion
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Abstract
Cardiac resynchronization therapy (CRT) is a new treatment for refractory heart failure. However, most heart failure 
patients treated with CRT are middle-aged or old patients with idiopathic or ischemic dilated cardiomyopathy. We 
treated a 17 year 11 month old girl with dilated cardiomyopathy after mitral valve replacement (MVR) and septal 
anterior ventricular exclusion (SAVE). Seven years after the SAVE procedure, she presented complaining of palpitations 
and general fatigue with normal activity. Her echocardiogram showed reduced left ventricular function. Despite of 
optimal medical therapy, her left ventricular function continued to decline and she experienced regular arrhythmias 
such as premature ventricular contractions. We thus elected to perform cardiac resynchronization therapy with 
defibrillator (CRT-D). After CRT-D, her clinical symptoms improved dramatically and left ventricular ejection fraction 
(LVEF) improved from 31.2% to 51.3% as assessed by echocardiogram. Serum BNP levels decreased from 448.2 to 213.6 
pg/ml. On ECG, arrhythmias were remarkably reduced and QRS duration was shortened from 174 to 152 msec. In 
conclusion, CRT-D is an effective therapeutic option for adolescent patients with refractory heart failure after left 
ventricular volume reduction surgery.
Background
Left ventricular volume reduction therapy has been an
effective treatment modality for end-staged dilated cardi-
omyopathy. Some patients, however, suddenly worsen
due to leading to heart failure. To address asynchrony,
cardiac resynchronization therapy (CRT) was developed
and is recommended by the AHA 2009 guidelines [1].
More than 4000 heart failure patients with ventricular
asynchrony have been evaluated in randomized con-
trolled trials of optimal medical therapy alone versus
optimal medical therapy plus CRT. CRT has resulted in
significant improvements in the quality of life, functional
class, exercise tolerance, and ejection fraction [2-5] in
patients with refractory heart failure. But most patients
are middle-aged and older adults with ischemic heart dis-
ease. Moreover, there are no guidelines for pediatric
patients. Here we report the successful use of CRT in an
adolescent girl after septal anterior ventricular exclusion
(SAVE) procedure during childhood.
Case Presentation
In December 2009, a 17 year, 11 month old adolescent
girl with history of worsening dilated cardiomyopathy
after mitral valve replacement (MVR) and septal anterior
ventricular exclusion (SAVE) was admitted to our hospi-
tal for the evaluation for cardiac resynchronization ther-
apy (CRT).
At two months of age, a heart murmur was noted on
examination and one year later, she was diagnosed with
congenital mitral valve stenosis (MS) and mitral valve
regurgitation (MR). Despite optimal medical therapy
(digitoxin and diuretics), her left ventricular end-diastolic
diameter (LVDd) gradually increased and her MR wors-
ened. She underwent MVR at age six, but the cardiac
function deteriorated and LVDd progressively increased.
At age 11 years and 1 month, she went into a cardiogenic
shock and emergently underwent SAVE and a second
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MVR procedure emergently. She successfully recovered
from cardiogenic shock and the physical activity
improved from New York Heart Association (NYHA)
class IV to class II [6].
Her cardiac function has remained stable for six years
following the SAVE procedure. In June 2008, six years
after the SAVE and second MVR procedures, she devel-
oped palpitations and general fatigue with regular activ-
ity. The LVDd was again dilated, and the left ventricular
ejection fraction (L VEF) decreased. In the course of six
months prior to her hospitalization, the serum BNP
increased from 148.6 pg/ml to 493.1 pg/ml. In addition,
QRS duration suddenly widened from 126 msec to 182
msec. Tissue doppler echocardiogram confirmed a clear
asynchrony. We recommended CRT placement given her
worsening heart failure following left ventricular volume
reduction therapy.
At the time of admission, her body weight and height
was 33.0 kg and 143.0 cm. The chest X-ray revealed sig-
nificant increases in cardio-thoracic ratio (CTR) (70.6%)
and pulmonary congestion. Echocardiogram showed
LVDd of 59.3 mm (134.2% of normal), and reduced LVEF.
LVEF was also measured by a cardiac MRI, and was esti-
mated to be 23.7%. Serum BNP was again elevated at
448.4 pg/ml. Her ECG showed widened QRS duration of
174 msec and complete left bundle branch block
(CLBBB) (Figure 1A). We concluded that cardiac asyn-
chrony was probably responsible for her worsening heart
failure. She was immediately scheduled for CRT place-
ment.
On the third day of hospitalization, CRT with defibrilla-
tor (CRT-D) implantation was performed by transvenous
approach. We chose CRT-D, Medtronic Concerto
C154DWK, because she experienced arrhythmias such as
premature ventricular contractions (PVC), non-sustained
ventricular tachycardia and atrial flutter. Before the CRT
implantation, we assessed asynchrony by tissue doppler
echocardiogram and determined the most delayed site of
the whole wall movement. We targeted the most delayed
site as the optimal pacing site. But the strong degenera-
tion of cardiac muscles restricted the possible pacing site.
We placed an atrial lead at the right appendage and a RV
lead at the apex. A LV lead was placed at the lateral wall of
the coronary sinus because there was the possibility that
the main trunk of the coronary sinus was occluded during
the SAVE procedure assessed by contrast medium. We
show the final pacing site by the chest X-ray (Figure 2).
The pacemaker mode was DDD 60-130 bpm biventricu-
lar pacing. While testing the implantable cardioverter-
defibrillator (ICD), a 10 J defibrillation was administered
for ventricular fibrillation. All segmental max delay and
all segmental standard deviation improved from 140
msec to 86 msec and 44 msec to 26 msec, respectively, by
tissue doppler echocardiogram. Three months after the
CRT-D implantation, the LVEF improved from 31.2% to
51.3% (Figure 3) and the serum BNP levels decreased
from 448.2 to 213.6 pg/ml. The QRS duration was short-
ened from 174 to 152 msec (Figure 1B), and arrhythmias
were extremely reduced. By a Holter monitoring, the
number of PVCs reduced from 3625 to 127 and double-
barreled PVCs reduced from 101 to 1 per 24 hours. The
physical activity improved remarkably and the NYHA
classification improved from class III to class II for
around one year. She was able to resume her previous
level of activity.
Figure 1 ECG before and after the CRT placement. Before the CRT 
placement (A), QRS duration was prolonged as 174 msec. In addition, 
ECG showed the prolonged PR interval and complete left bundle 
branch block (CLBBB). After the CRT placement (B), the QRS duration 
was shortened to 152 msec. In addition, PR interval was shortened and 
CLBBB changed to complete right bundle branch block (CRBBB).
 
Figure 2 The chest X-ray (PA and Lateral projection) after the CRT 
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Conclusion
CRT has become an accepted method for treating refrac-
tory heart failure in patients with idiopathic or ischemic
dilated cardiomyopathy associated with electromechani-
cal asynchrony. In the current AHA guidelines, CRT is a
class I (level of evidence A) therapy for patients with a
LVEF less than or equal to 35% and a QRS duration
greater than or equal to 120 msec who are symptomatic
(NYHA functional Class III or IV) despite optimal rec-
ommended medical therapy [7]. At the time of our
patient's admission, she meets all these criteria despite
optimal medical therapy. We thus thought that she was
an appropriate candidate for CRT.
CRT may be performed with or without defibrillator. In
the CARE-HF (Cardiac Resynchronization in Heart Fail-
ure) trial, a randomized controlled trial comparing opti-
mal medical therapy alone with optimal medical therapy
plus CRT without a defibrillator, CRT significantly
reduced the combined risk of death of any cause or
unplanned hospital admission for major cardiovascular
events (analyzed as time to first event) by 37% [8]. In the
COMPANION (Comparison of Medical Therapy, Pacing,
and Defibrillation in Heart Failure) trial, directly com-
pared pacing with CRT-D and CRT without defibrillation
with optimal medical therapy, only CRT-D reduced sud-
den cardiac death (SCD) [9,10]. Although there was
insufficient evidence to conclude that CRT alone was
i n f e r i o r  t o  C R T - D ,  w e  s e l e c t e d  C R T - D  i n  o u r  p a t i e n t
because of her repeated arrhythmias.
The efficacy of CRT in the young and in those with
congenital heart disease (CHD) has not yet been estab-
lished because the vast majority of patients included in
randomized clinical studies of CRT have cardiomyopathy
of ischemic or idiopathic etiology and most patients are
middle-aged and older adults. Although there are no pro-
spective trial data, retrospective series show that CRT is
similarly effective for managing asynchrony-associated
heart failure in the younger population as it is for treating
adults with ischemic and idiopathic dilated cardiomyopa-
thy [11,12]. And our case demonstrates that CRT is a use-
ful adjunct in the treatment of heart failure in the young
after the LV volume reduction surgery. In addition, CRT
has been discussed as an alternative to cardiac transplan-
tation in advanced heart failure. Bert Hansky et al. dem-
onstrate that CRT is a reliable therapeutic option for the
long-term treatment of end-stage heart failure and LV
asynchrony [13]. In many countries, cardiac transplanta-
tion is difficult because donors are particularly rare. This
is one of the reasons why we elected to perform CRT.
CRT also may become a bridge to transplant that offers
extended patient longevity and improved quality of life to
younger patients with CHD and end-stage heart failure
[14]. Our case demonstrates the merit of such a concept.
We conclude that CRT is a useful adjunct in the treat-
ment of heart failure in adolescents after the SAVE proce-
dure. We propose that CRT is a promising modality for
the treatment of refractory heart failure with asynchro-
nous LV wall motion. Further studies are needed to deter-
mine the indication, effectiveness, and the long-term
benefits of this therapy in the pediatric population.
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Figure 3 Echocardiogram before and after the CRT placement. 
Each panel shows the short axis view of the LV cavity. Upper panels: 
The LVDd was 59.3 mm and LVEF was 31.2% before the CRT placement. 
Lower panels: The LVDd was 61.3 mm and LVEF was 51.3% after the 
CRT placement.
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